Management to host conference call on
Company also to present at the Biotech Showcase
Date: | |
Time: | |
Dial-in: | 1-888-886-7786 |
Webcast Link: | Click HERE |
Biotech Showcase Presentation | |
Date: | |
Time: | |
Location: | |
Webcast: | Click HERE |
A replay of both the conference call and Biotech Showcase presentation will be available on the investor’s portion of the company’s website.
About
The company’s product pipeline includes iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs, and multiple partnered PDC assets. The company is currently investigating iopofosine in a global, open-label, pivotal expansion cohort in relapsed or refractory WM patients who have received at least two prior lines of therapy, including those who have failed or had a suboptimal response to Bruton tyrosine kinase inhibitors. The WM cohort is designed to evaluate the efficacy and safety of iopofosine for marketing approval. The company is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase 2 CLOVER-1 study and relapsed/refractory pediatric cancer patients with brain tumors in the Phase 1 CLOVER-2 study.
The Phase 1 pediatric study is an open-label, dose-finding study to evaluate the activity and safety of different dosages and dosing regimens of iopofosine in children and adolescents with relapsed or refractory brain tumors. The study is being conducted in up to fifteen leading pediatric cancer centers in
The company has established exclusivity on a broad
In addition to the company’s exclusivity to iopofosine and its phospholipid ethers conjugated to small molecules, peptides, and oligos, the company now has non-exclusive rights to the use of the phospholipid ether platform when conjugating with a chelator to bind select metal radioisotopes.
For more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
MEDIA:
315-765-1462
clacagnina@blissbiohealth.com
INVESTORS:
Chief Financial Officer
investors@cellectar.com
Source:
2024 GlobeNewswire, Inc., source